In these unprecedented times, we provide an early release episode to gain insight on dealing with the COVID-19 pandemic from Deputy Editor in Chief of US Cardiology Review, a BDG interventional cardiologist, Bill Gogas, MD, PhD practising in East Asia.
Hear Bill’s take on how East Asia responded to and successfully managed the pandemic and how they are now seeing a significant reduction in cases outside the epicentre. Hear how the strategy resulted in only 93 patients in Bill’s city of Nanjing, testing positive for coronavirus with a city population of 8 million.
Learn about effective responses, the importance of early control and how as a cardiovascular physician, your life and practice may be impacted by the virus.
Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
In this latest episode, Ankur Kalra, MD meets with Andrew Sauer, MD, co-author of an upcoming paper in US Cardiology Review on COVID-19 and Cardiovascular Disease that provides a concise and current summary of cardiovascular complications from COVID-19.
Hear them discuss the latest issues surrounding the pandemic, the known cardiac implications and the rapidly emerging data.
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.